The home infusion provider beat sequential expectations, narrowing full-year EBITDA and EPS guidance while maintaining revenue outlook.
Option Care Health reported second-quarter revenue of $1.4 billion, a 7% sequential increase, driven by high-single-digit organic growth in acute therapies. Adjusted EBITDA rose 12% to $117.5 million, while adjusted EPS reached $0.45, exceeding internal forecasts.
The company maintained its full-year revenue guidance of $5.675 billion-$5.775 billion but narrowed adjusted EBITDA to $480 million-$495 million and adjusted EPS to $1.85-$1.92. Chronic revenue improved sequentially, though CID-related pressure is expected to cut 2026 revenue by 600 basis points and gross profit by $55 million.
Operating cash flow totaled $184 million, and the company repurchased $150 million in shares, nearly 5% of outstanding stock. Shares traded lower despite the earnings beat.